

References

I-100

1. Kjersem JB, Skovlund E, Ik Dahl T, et al. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil-folinic acid and oxaliplatin +/- cetuximab. *BMC Cancer*. 2014;19;14(1):340.
2. ERBITUX® (cetuximab) [package insert]. Branchburg, NJ. ImClone Systems Incorporated. 2015.
3. Carthon B, Ng C, Peltaway C, et al. Epidermal growth factor receptor–Targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. *BJU International*. 2014;113(6): 871-877.
4. Lin L, Chen L, Wang Y, et al. Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. *Molecular and Clinical Oncology*. 2016;4:1017-1024.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Penile cancer. Version 2.2016.
6. MICROMEDEX®SOLUTIONS Compendia. 2018. Cetuximab.
7. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Cetuximab.
8. NCCN Drugs & Biologics Compendium™. Cetuximab. 2018. National Comprehensive Cancer Network (NCCN).
9. Privitera G, Luca T, Musso N, et al. In vitro antiproliferative effect of trastuzumab (Herceptin_) combined with cetuximab (Erbitux_) in a model of human non-small cell lung cancer expressing EGFR and HER2. *Clin Exp Med*. 2016;16:161–168.
10. Carvalho AC, Leal F, Sasse AD. Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer. *PLoS ONE*. 12(4):e0175409.
11. Lieu CH, Messersmith WA. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer No Difference, but Not the Same. *JAMA*. 2017;2376-2378.